More than a decade after earning FDA approval for Xiaflex as a nonsurgical treatment option for Dupuytren’s contracture, Endo is debuting its first-ever branded TV commercial in the indication. More: Endo highlights a Xiaflex success story in first branded commercial
read moreArnie told us he’d be back. Three months after becoming Zimmer Biomet’s chief movement officer, the quintessential action hero has returned to front a campaign that puts a twist on his famous “I’ll be back” catchphrase to motivate people living
read moreThe government price negotiations affecting Keytruda wouldn’t take effect until 2028, Merck said in its annual securities filing. That year will also see a key patent loss for the drug. More: Merck expects oncology king Keytruda to face IRA 'price
read more
Data presented in Los Angeles showcases therapy’s potential More: Microbiotica unveils new data on MB097 at AACR IO meeting Source: News
read more
Updated data from phase 2 study reveals survival benefit More: Mitazalimab shows promising survival rates in cancer study Source: News
read moreMerely a minute into his prepared remarks during Jazz Pharmaceuticals’ fourth-quarter earnings call, CEO Bruce Cozadd brought investors’ attention to the company’s appetite in dealmaking. More: Jazz 'active and looking' at M&A deals of 'various sizes' as it wraps up
read more© 1994 - 2025 B.M. Pharmaceuticals